New drug shows promise against Tough-to-Treat blood cancer
NCT ID NCT04318080
Summary
This study tested an immunotherapy drug called tislelizumab in 46 adults whose classical Hodgkin lymphoma had returned or did not respond to prior treatments. The goal was to see if the drug could shrink tumors and control the cancer. Participants received the drug until their cancer progressed or side effects became too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-2013, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
University of Tennessee Medical Center
Knoxville, Tennessee, 37920-1511, United States
Conditions
Explore the condition pages connected to this study.